NDLI: Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Morfin-Otero, Rayo Dowzicky, Michael J.
Spatial Coverage	Europe Africa North America Latin America Middle East Asia
Description	Country affiliation: Mexico Author Affiliation: Morfin-Otero R ( Hospital Civil de Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.)
Abstract	BACKGROUND: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) began in 2004 to monitor global antimicrobial susceptibility to tigecycline and a range of comparator antimicrobials among gram-positive and gram-negative organisms. OBJECTIVE: The aim of this study was to report changes in MIC for tigecycline and other antimicrobial agents among 10,149 Acinetobacter baumannii isolates collected globally between 2004 and 2009. METHODS: MICs of 10,149 isolates were determined locally using Clinical Laboratory and Standards Institute (CLSI) methodologies. Antimicrobial susceptibility was ascertained according to CLSI interpretive criteria (no interpretive criteria have been approved for tigecycline against Acinetobacter spp). RESULTS: Increases in resistance were noted for most antimicrobial agents in all regions. Significant (P < 0.05) increases in percentage resistance were reported for all antimicrobial agents globally. The smallest changes in cumulative geometric mean MICs were reported for tigecycline (0.2 mg/L) and cefepime (3.5 mg/L). MIC(90)s were at the top of their testing ranges for most agents against both multidrug-resistant (MDR) and non-MDR isolates; only tigecycline showed little change in MIC(90) between MDR (2 mg/L) and non-MDR (1 mg/L) isolates. Resistance was higher among isolates from the intensive care unit (ICU) compared with non-ICU isolates. CONCLUSION: These findings suggest that resistance is increasing among clinical isolates of A baumannii globally. Although resistance to tigecycline has been reported in the treatment of infections caused by A baumannii, it retains in vitro activity against this pathogen.
File Format	HTM / HTML
ISSN	01492918
Issue Number	1
Volume Number	34
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2012-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Acinetobacter Infections Drug Therapy Acinetobacter Baumannii Drug Effects Anti-bacterial Agents Therapeutic Use Drug Resistance, Multiple, Bacterial Microbial Sensitivity Tests Minocycline Analogs & Derivatives Epidemiology Microbiology Isolation & Purification Pathogenicity Africa Asia Dose-response Relationship, Drug Europe Humans Intensive Care Units Latin America Middle East North America Time Factors Comparative Study Journal Article Multicenter Study Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).

Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.

Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).

In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.

Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.

Intravitreal tigecycline treatment in experimental Acinetobacter baumannii endophthalmitis. (Journal: Journal of Chemotherapy Volume: 24 Issue: 5)

Therapeutic options for Acinetobacter baumannii infections.

Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.

Similar Documents

Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).

Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.

Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).

In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.

Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.

Intravitreal tigecycline treatment in experimental Acinetobacter baumannii endophthalmitis. (Journal: Journal of Chemotherapy Volume: 24 Issue: 5)

Therapeutic options for Acinetobacter baumannii infections.

Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.